Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Phase III and Extended Phase III Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Cancer or Suspected Cancer

NCT00123760 is registered in ClinicalTrials.gov with AHS Cancer Control Alberta as lead sponsor.

NCT NCT00123760
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00123760 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Phase III and Extended Phase III Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Cancer or Suspected Cancer
Lead sponsor
AHS Cancer Control Alberta
Phase
Phase 2/3
Overall status
Completed
Start date
February 29, 2004
Completion date
December 31, 2008
Enrollment
10,838 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain neoplasms, colorectal neoplasms, lung neoplasms, lymphoma, thyroid neoplasms